. Author manuscript; available in PMC: 2014 Sep 1.

Published in final edited form as: Pharmacogenet Genomics. 2013 Sep;23(9):470–478. doi: 10.1097/FPC.0b013e328363c137

Table 1.

Participant characteristics of angioedema cases and ACE inhibitor-exposed controls in the Nashville/Marshfield GWAS

	Cases (175) [n (%)]	Controls (489) [n (%)]
Age (years)	58.4±14.1	61.7±13.1
Sex (male : female)	79 (45.1) : 96 (54.9)	229 (46.8) : 260 (53.2)
Race (unknown : African : European)	0 : 66 (37.7) : 109 (62.3)	2 (0.4) : 157 (32.1) : 330 (67.5)
Current smoker (unknown : no : yes)	28 (16.0) : 110 (62.9) : 37 (21.1)	110 (22.5) : 288 (59.0) : 91 (18.6)
Diabetic (missing : no : yes)	1 (0.6) : 116 (66.3) : 58 (33.1)	7 (1.4) : 300 (61.4) : 182 (37.2)
Seasonal allergy (missing : no : yes)	47 (26.9) : 43 (24.6) : 85 (48.6)	152 (31.1) : 183 (37.4) : 154 (31.5)
Current ACE inhibitor (missing : no : yes)	1 (0.6) : 117 (66.9) : 57 (32.6)	7 (1.4) : 143 (29.4) : 339 (69.3)

At Vanderbilt, some cases were ascertained during their acute episode of angioedema and were thus taking an ACE inhibitor at the time of ascertainment. ACE, angiotensin-converting enzyme.